Evaluation of overall toxicity of high‐dosage methotrexate regimens

Clara Perez, Wataru W. Sutow, Y. M. Wang, Jay Herson

Research output: Contribution to journalArticlepeer-review

Abstract

The occurrence of overall toxicity was analyzed for 43 patients with osteosarcoma who received 349 high‐dosage courses of methotrexate (HD‐MTX) with citrovorum factor (Leukovorin) „rescue” (CF). The dosages of HD‐MTX ranged from 50 to 350 mg/kg. Overall toxicity was assessed on the basis of five manifestations of toxicity: stomatitis, dermatitis, myelosuppression, liver dysfunction, and kidney function abnormalities. The great majority (91.4%) of the infusions were well tolerated, but 8.6% were associated with moderate or severe toxicity. Stomatitis and serum glutamic‐oxaloacetic transaminase (SGOT) changes were the most frequent postinfusion findings. Three patients died from causes related to MTX toxicity. Dose, age, sex, and number of prior infusions were investigated by logistic regression analysis for prognostic effect on frequency of moderate to severe overall toxicity. Age and number of prior infusions had significant (P < 0.06) effects on overall toxicity. Patients older than 15 years with greater than 10 prior infusions constituted the „high risk” group with a risk of moderate to severe toxicity 6.3 times that of the younger patients with fewer than 10 infusions.

Original languageEnglish (US)
Pages (from-to)219-228
Number of pages10
JournalMedical and Pediatric Oncology
Volume6
Issue number3
DOIs
StatePublished - 1979
Externally publishedYes

Keywords

  • chemotherapy
  • methotrexate
  • osteosarcoma
  • toxicity

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Evaluation of overall toxicity of high‐dosage methotrexate regimens'. Together they form a unique fingerprint.

Cite this